Regeneron Pharmaceuticals (REGN) said late Friday that the US Food and Drug Administration issued a complete response letter rejecting its request to add extended dosing intervals for Eylea HD injection 8 mg across all approved indications.
The company said the health agency raised no concerns about the drug's safety or efficacy but declined to approve the extended schedule.
The drugmaker said it is reviewing the decision and considering the next steps.
Eylea HD is approved to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.